Necitumumab Drug Asset Due Diligence Report 2026

This Necitumumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Necitumumab can convert its Monoclonal antibody profile and EGFR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Necitumumab (query alias: necitumumab)
Modality / target	Monoclonal antibody; EGFR; EGFR antagonists
Highest global status	Approved
Originator	Eli Lilly & Co.
Active developers	Eli Lilly & Co., Nippon Kayaku Co., Ltd., Eli Lilly Canada, Inc.

The MCP disease footprint includes Squamous non-small cell lung cancer, Non-Small Cell Lung Cancer, Non-squamous non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2031240655	Phase 2	Recruiting	34	Overall response rate
JPRN-jRCTs041220070	Phase 2	Not Recruiting	22	客観的奏効割合
JPRN-jRCT2021210079	Phase 1/2	Recruiting	55	＜第 I 相パート＞用量制限毒性（DLT：Dose Limiting Toxicity）最大耐用量（MTD：Maximum Tolerable Dose）推奨用量（RD：Recommended Dose）＜第 II 相パート＞奏効率（ORR：Objective Response Rate）中央画像判定

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Durable efficacy of first-line necitumumab plus pembrolizumab in PD-L1–high advanced NSCLC: Final results of the phase II K-TAIL-202 study.

Phase 2; n=50; evaluation: Positive. Reported fields: ORR = 68.0 % ( 53.3 - 80.5)

931P - A phase II basket study of necitumumab for EGFR amplification–positive metastatic solid tumors: WJOG15021M

Phase 2; n=22; evaluation: Negative. Reported fields: -; RR = 38.0 % ; RR = 25.0 %

1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study

Phase 2; n=46; evaluation: Positive. Reported fields: ORR = 26.1 % (80%CI, 17.7 - 36.2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Necitumumab addresses Squamous non-small cell lung cancer, Non-Small Cell Lung Cancer, Non-squamous non-small cell lung cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-04-22	NIPPON KAYAKU and Eli Lilly Enter into Licensing Agreement of Necitumumab, a humanized anti EGFR Monoclonal Antibody, in JAPAN	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “CDK inhibitors conjugated to EGFR targeting moieties”. The milestone feed surfaced a patent-application signal described as “Combination therapy comprising a KRAS g12d inhibitor and an EGFR inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO